HK2 overexpression
|
CRC
|
HK2 overexpression
|
CRC
|
cetuximab Sensitive: C3 – Early Trials
|
cetuximab Sensitive: C3 – Early Trials
|
HK2 overexpression
|
AML
|
HK2 overexpression
|
AML
|
daunorubicin Resistant: D – Preclinical
|
daunorubicin Resistant: D – Preclinical
|